Negev Capital

Negev Capital is a venture capital firm specializing in early-stage investments in companies developing psychedelic medical interventions for neuropsychiatric disorders. The firm focuses on drug discovery, particularly in the preclinical and Phase 1 stages of development, aiming to support companies that promote the responsible and therapeutic use of psychedelic medications. Negev Capital seeks to partner with companies that have strong management teams, robust intellectual property, and a commitment to advancing psychedelic therapies.

The firm's investment strategy centers on identifying and supporting companies that are at the forefront of psychedelic research and development. By providing capital and strategic guidance, Negev Capital aims to accelerate the maturation of the psychedelic medicine field and facilitate the delivery of these treatments to individuals in need. The firm is committed to reducing human suffering through innovative medical interventions and believes in the transformative potential of psychedelic therapies in psychiatry.

Negev Capital's portfolio includes investments in companies such as Filament Health, a clinical-stage natural psychedelic drug development company, and Clairvoyant Therapeutics, a Canadian biotechnology firm focused on psilocybin therapy for Alcohol Use Disorder. These investments reflect Negev Capital's dedication to advancing the field of psychedelic medicine and supporting companies that are pioneering new treatments for mental health conditions.